← Back to Search

Stereotactic Radiation Therapy for Uterine Cancer

N/A
Waitlist Available
Led By David D'Souza, M.D.
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients who have undergone hysterectomy for curative intent, with histologically confirmed endometrioid adenocarcinoma, serous or clear cell carcinoma, or carcinosarcoma or dedifferentiated carcinoma
Age ≥18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 2 years post-treatment.
Awards & highlights

Study Summary

This trial is testing whether a new radiation treatment for endometrial cancer is effective and safe. The new treatment delivers a higher dose of radiation in fewer fractions than the current standard of care.

Who is the study for?
This trial is for adults who've had a hysterectomy to treat certain uterine cancers (like endometrioid adenocarcinoma, serous or clear cell carcinoma) and are candidates for additional radiation therapy. They must understand English or their language should have the required questionnaires, be willing to consent to the study, and complete quality of life surveys.Check my eligibility
What is being tested?
The trial tests a type of targeted radiation therapy called SBRT with a specific dose thought to be effective yet safe. It aims at delivering high precision treatment while minimizing damage to healthy tissue in patients who've undergone surgery for uterine cancer.See study design
What are the potential side effects?
While not explicitly listed, side effects may include typical reactions associated with pelvic radiation such as fatigue, skin irritation in the treated area, digestive issues like diarrhea or discomfort during urination due to inflammation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had a hysterectomy for cancer, specifically endometrioid adenocarcinoma, serous, clear cell carcinoma, carcinosarcoma, or dedifferentiated carcinoma.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 2 years post-treatment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 2 years post-treatment. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assess the acute urinary and bowel toxicities

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
656 Previous Clinical Trials
413,398 Total Patients Enrolled
David D'Souza, M.D.Principal InvestigatorLondon Regional Cancer Program

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT04458597 — N/A
Endometrioid Adenocarcinoma Research Study Groups:
Endometrioid Adenocarcinoma Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT04458597 — N/A
Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT04458597 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.
2020. "Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04458597.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top